Research is a cornerstone of our mission at PARSGO, driving our commitment to improving the lives of women affected by gynecologic cancers. We are dedicated to advancing the understanding of these cancers through innovative research initiatives tailored to address the specific challenges faced by women in the MENA and Sub-Saharan regions.

In these areas, gynecologic cancers often remain under-researched and underfunded, presenting significant barriers to effective treatment and patient care. Especially in the MENA and African regions, research data is notably less comprehensive compared to the Global North, highlighting the urgent need for targeted investigations that reflect the unique demographics and healthcare systems of these populations. At PARSGO, we recognize this gap and strive to fill it by conducting high-quality research that informs clinical practices and enhances patient outcomes.

Our research initiatives focus on various aspects of gynecologic oncology, including early detection, treatment efficacy, survivorship, and psychosocial impacts, ensuring that our efforts encompass the full spectrum of women’s health issues.

By collaborating with global partners, academic institutions, and healthcare organizations, we aim to conduct studies that not only contribute to the local body of knowledge but also facilitate an international exchange of ideas and best practices. This collaborative approach enhances our ability to develop evidence-based treatment protocols that reflect the latest advancements in the field.

Moreover, our commitment to research allows us to participate actively in clinical trials and studies that evaluate new therapies and interventions. Through this work, we strive to develop better patient care strategies and improve treatment protocols tailored to the unique needs of women in our regions.

Ultimately, our research efforts lead to better healthcare outcomes for women affected by gynecologic cancers, empowering them with the knowledge and resources necessary to navigate their treatment journeys. By fostering a culture of inquiry and innovation, we not only improve the standard of care locally but also contribute to the global dialogue on gynecologic health.

We are proud to share a list of our publications that reflect our research initiatives and findings:

• Nasser S, Bilir E, David A, Gultekin M, Sehouli J. Building research competency across low and middle resource settings: an ENGOT initiative and NOGGO mentorship program at the ESGO 2022 in Berlin. Int J Gynecol Cancer. 2024 Jan 5;34(1):163-164. doi: 10.1136/ijgc-2023-005019. PMID: 38016756.
• Kouhen F, Ghazi B, Nasser S, Sehouli J, El Ghanmi A. PARSGO and UM6SS: spearheading excellence in gynecological oncology in Morocco. Int J Gynecol Cancer. 2024 Oct 7;34(10):1647-1648. doi: 10.1136/ijgc-2024-005393. PMID: 38658023.
• Nasser S, Togo PA, Elghanmi A, Bilir E, Sehouli J. Call for implementation research: cross-continental partnership experiences from the Trans-African Digital e-Health Network (i-STARC Project). Int J Gynecol Cancer. 2023 Sep 4;33(9):1469-1470. doi: 10.1136/ijgc-2021-003274. PMID: 36707084.
• Nasser S, Fotopoulou C, Gültekin M, Dimitrova D, Bilir E, Inci G, Morice P, Mirza MR, Martin AG, Berek J, Sehouli J; Collaborating Groups: European Network for Gynaecological Oncology Trials (ENGOT), European Society for Gynaecological Oncology (ESGO), Gynecological Cancer Intergroup (GCIG), Pan-Arabian Research Society for Gynecological Oncology (PARSGO), North-East German Gynecological Oncology Society (NOGGO). Patient care and access to clinical trials in gynaecological oncology: global implications of the early phase of the COVID-19 pandemic. Arch Gynecol Obstet. 2024 Jul;310(1):577-586. doi: 10.1007/s00404-024-07511-4. Epub 2024 Jun 5. PMID: 38836928; PMCID: PMC11168972.
• Nasser S, Bilir E, Derin X, Richter R, Grabowski JP, Ali P, Kulbe H, Chekerov R, Braicu E, Sehouli J. Pre-Operative Malnutrition in Patients with Ovarian Cancer: What Are the Clinical Implications? Results of a Prospective Study. Cancers (Basel). 2024 Jan 31;16(3):622. doi: 10.3390/cancers16030622. PMID: 38339372; PMCID: PMC10854561.
• Kacperczyk-Bartnik J, Bilir E, Nasser S, Strojna A, Eriksson AGZ. Is it possible to block cancer? The example of #VaginalCancer on Instagram. Int J Gynecol Cancer. 2023 Sep 4;33(9):1488-1489. doi: 10.1136/ijgc-2023-004844. PMID: 37591610.

Abstracts:

• Nasser S, Bilir E, Kaufmann A, et al #175 Empowerment and participation of women within clinical trials (EMPACT): a research program protocol in gynaecologic oncology, International Journal of Gynecologic Cancer 2023;33:
• Nasser S, Ahmed W, Bilir E, et al #186 Instagram analysis of discussions and trends in vaginal cancer: insights from a european network of young gynaecologic oncologists (ENYGO) study International Journal of Gynecologic Cancer 2023;33:

By continuously striving for excellence in research, PARSGO remains committed to advancing gynecologic oncology and ensuring that women receive the care and support they deserve.